1. Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model 
Saad S. Kenderian, Marco Ruella, Olga Shestova, Miriam Kim, Michael Klichinsky, Fang Chen, Natalka Kengle, Simon Lacey, Jan Melenhorst, Carl H. June, Saar I. Gill 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 3, Pages S19-S20 (March 2017)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Ruxolitinib treatment ameli or ates CRS after CART cell therapy.
Biology of Blood and Marrow Transplantation  , S19-S20DOI: ( /j.bbmt )
Copyright © Terms and Conditions